Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition

Posted
Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies. The post Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition appeared first on MedCity News.

Continue reading at MedCity News »

BioPharma, Pharma, Startups, argenx, Deals, immunology, inflammation, Mergers and Acquisitions, oral peptide, Peptides, Unnatural Products